Study suggests that cancer patients less protected than others after one dose of Pfizer vaccine.
The UK government decided to extend the time between doses to 12 weeks instead of the recommended three to give more people more protection as soon as possible. While Clinically Extremely Vulnerable people such as people with cancer have been prioritised for the first dose of the vaccine, a study at King's College London and Francis Crick Insititute suggests that this group needs an earlier second dose to have the same protection as the rest of the population.
While the study is relatively small and is ongoing, we are joining other cancer organisations in calling on the Joint Committee on Vaccination and Immunisation (JCVI) to review the results of the study and consider adapting its strategy so that people with cancers can access the second dose of the vaccine more quickly.
In the meantime, we ask that anyone with sarcoma or other cancers get the vaccine (you can book it yourself right now) and continue to follow advice from your healthcare practitioner.